{"title":"Rituximab therapy for chronic lymphocytic leukaemia","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.37","DOIUrl":null,"url":null,"abstract":"<p>Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.37","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.37","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.
利妥昔单抗治疗慢性淋巴细胞白血病
慢性淋巴细胞白血病(CLL)的严重程度各不相同，一些患者需要化疗，而另一些患者可能根本不需要治疗。利妥昔单抗已被评估为需要化疗的CLL患者联合氟达拉滨和环磷酰胺的一线治疗选择，并已提出许可申请。在本文中，我们考虑了利妥昔单抗的证据，以及它在治疗中的潜在地位。版权所有©2008 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
